Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.
Malignant gliomas are the most common primary brain tumors. Despite intensive clinical investigation and many novel therapeutic approaches, average survival for the patients with malignant gliomas is only about 1 year. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has shown potent and cancer-selective killing activity and drawn considerable attention as a promising therapy for cancers, but concerns over delivery and toxicity have limited progress. We have developed a secretable trimeric TRAIL (stTRAIL) and here evaluated the therapeutic potential of this stTRAIL-based gene therapy in brain tumors. An adenovirus (Ad-stTRAIL) delivering stTRAIL was injected into intra-cranial human glioma tumors established in nude mice and tumor growth monitored using the magnetic resonance imaging (MRI). Ad-stTRAIL gene therapy showed potent tumor suppressor activity with no toxic side effects at therapeutically effective doses. When compared with 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU), a conventional therapy for malignant gliomas, Ad-stTRAIL suppressed tumor growth more potently. The combination of Ad-stTRAIL and BCNU significantly increased survival compared to the control mice or mice receiving Ad-stTRAIL alone. Our data indicate that Ad-stTRAIL, either alone or combined with BCNU, has promise as a novel therapy for malignant gliomas.
Jeong
Moonsup
M
Biopharmaceutical Research Laboratories of Dong-A Pharmaceutical Co, Ltd, Kyunggi-Do, Korea.
Kwon
Yong-Sam
YS
Park
Soon-Hye
SH
Kim
Chae-Young
CY
Jeun
Sin-Soo
SS
Song
Kang-Won
KW
Ko
Yong
Y
Robbins
Paul D
PD
Billiar
Timothy R
TR
Kim
Byong-Moon
BM
Seol
Dai-Wu
DW
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D002330:Carmustine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D051379:Mice; D009368:Neoplasm Transplantation; D015996:Survival Rate; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000008:administration & dosage*; D016896:Treatment Outcome; D047368:Tumor Burden
D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; D002330:Carmustine